AZTA +20.21% ^GSPC +1.31% Trade Azenta on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Wednesday was an ideal day to be invested in Azenta's (NASDAQ:AZTA) stock. Investors fell over themselves buying shares of the healthcare tech company, and when the scramble subsided, the stock had gained almost 21%. That made it an outlier even in a prosperous trading session for the broader market, with the bellwether S&P 500 index posting a relatively strong 1.3% gain.
Azenta, which concentrates on automated sample storage for the healthcare industry, took the wraps off its fiscal fourth quarter of 2026. The company's revenue rose by 5% year over year to $167 million, driven by a 9% increase in its key sample management solutions unit to $94 million. Its other business, multiomics (analysis of numerous types of molecules at once), was flat at $73 million.
Missed AI's "Act 1"? Act 2 Could Be 16x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
On the bottom line, Azenta's net income not under generally accepted accounting principles (non-GAAP, or adjusted) was $12.3 million ($0.28 per share). That was up from the $9.6 million it netted in the same period of fiscal 2025.
Analysts were expecting worse. Their consensus estimate for revenue was barely over $160 million, while that for adjusted net profit was a mere $0.12 per share.
The company provided guidance for both the current quarter and the entirety of fiscal 2027. For the year, it's anticipating revenue will be $648 million to $660 million, with the adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin growing by 200 to 250 basis points over the 2026 result. It did not provide a bottom-line forecast.
Azenta sets itself apart from many current healthcare tech companies by focusing on sample storage. With this, it's selling its services into a large addressable market, as its solutions can deliver considerable cost and time savings for clients. I think its stock could go even higher after that considerable Wednesday pop, given the expected margin expansion, the company's clean balance sheet, and that considerable potential.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Azenta wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $341,157!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,037,753!*
Now, it's worth noting Stock Advisor's total average return is 834% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of November 11, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Why Azenta Stock Crushed it on Wednesday was originally published by The Motley Fool
